| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.092 | 0.05 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.069 | 0.1 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.057 | 0.3 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.047 | 0.3 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.047 | 0.3 |